NEW YORK (GenomeWeb News) – The international non-profit Drugs for Neglected Diseases Initiative (DNDi) and the Institut Pasteur Korea (IP-K) will collaborate to screen for and examine molecules that may be used as new treatments for certain "neglected" diseases, IP-K said today.

The two-year research agreement will focus on studying molecules that could be developed into treatments for leishmaniasis, which kills around 20,000 to 30,000 people per year, and Chagas disease, which affects around seven to eight million people every year.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.